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ABSTRACT 
Christopher K. Garrett: Characterization of a Key Mycobacterium tuberculosis 
Lipase, LipY  
(Under the direction of Saskia Neher) 
 
The causative agent of tuberculosis, Mycobacterium tuberculosis is estimated to 
be present in roughly a third of the world’s population. One of the hallmarks of the 
pathogen is its reliance on lipids as a source of energy in order to survive in a non-
replicating state and ultimately cause infection. A key player in lipid utilization by M. 
tuberculosis is the triglyceride lipase, LipY. LipY is the rate-limiting catalyst in the 
mobilization of free fatty acids from triglycerides acting on lipid bodies both within the 
tubercule bacillus and outside the bacterium. LipY also belongs to the PE/PPE family of 
proteins, a group of approximately 169 virulence-associated proteins characterized by a 
proline-glutamate or proline-proline-glutamate motif at their N-termini.  
It has been suggested that the PE domain of LipY may act as a regulator of 
enzymatic activity. Using several biochemical and activity-based approaches, we 
established a method for purifying LipY with improved resolution. We also introduced a 
rapid and reliable method for quantification of active sites for serine hydrolases using 
activity-based protein profiling (ABPP). Finally, by imploring these methodologies, we 
discovered that the PE domain of LipY acts as a non-competitive inhibitor of LipY 
enzymatic activity when it is attached to the mature lipase. The methodologies and 
evidence presented here may lead to discovery of additional PE/PPE family enzymes 
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with roles in M. tuberculosis lipid metabolism and/or virulence. This work may also lead 
to expansion of our understanding of the roles of PE/PPE proteins and domains. 
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To every Black boy and Black girl who has been told, “no, you can’t,” you can. And to 
the Trayvons, Mikes, Tamirs, Jordans and Sandras of the world, I see you. BLM. 
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CHAPTER 1: INTRODUCTION 
Tuberculosis Overview 
Mycobacterium Tuberculosis  
The tuberculosis (TB) disease is caused by a single deadly pathogen, 
Mycobacterium tuberculosis (M. tuberculosis), resulting in upwards of 9 million new 
infections and roughly 1.5 million deaths every year1. M. tuberculosis was first described 
as the causative agent of tuberculosis in 18822. Although M. tuberculosis can affect most 
tissues and organs (extrapulmonary TB), the majority of infections begin in the lungs 
(pulmonary TB) where alveolar macrophages phagocytose the bacteria1,3,4. Subsequently, 
most bacteria are destroyed although in a number of cases, the opportunistic pathogen is 
able to modulate the host’s response such that it avoids destruction and proliferates, 
ultimately leading to cell death and infection5-7.  
Ninety-five percent of all TB deaths occurred in developing countries around the 
world with 22 of those countries accounting for 80% of all TB cases1. M. tuberculosis is 
the second deadliest single causative agent in the world with HIV leading the way1. A 
vaccine widely used in countries where TB is most prevalent, bacillus Calmette-Guérin 
(BCG), is a strain derived from attenuation of the Mycobacterium bovis species8. 
However, the BCG vaccine is limited in its ability to protect individuals from certain 
forms of M. tuberculosis transmission9. When individuals with active TB infections 
cough, bacilli-containing sputum is released and can be inhaled resulting in TB infection. 
Those most susceptible to TB infection generally have weakened immune systems and 
 2 
 
include children, the elderly and individuals with HIV as TB-HIV co-infection can make 
up more than two thirds of all TB cases in certain developing countries10. 
 One of the major breakthroughs towards a more comprehensive understanding M. 
tuberculosis was the sequencing of its genome in 199811. M. tuberculosis is made up of 
roughly 4,000 genes spanning an approximately 4.4 million base pair genome11,12. One of 
the defining characteristics of the bacteria and sources of its name is a thick, waxy cell 
wall made up primarily of mycolic acids and other lipids that aid the pathogen in 
virulence and resistance to drugs13,14. M. tuberculosis is also considered a slow-growing 
pathogen, requiring up to 16 hours to double in cultured medium15. This is also one of the 
major features that allows infection to go undetected for extended periods of time. 
Treatment  
 One of the biggest impediments to drug effectiveness is the M. tuberculosis cell 
wall, an extremely hydrophobic layer with a variety of lipids, glycolipids and 
polysaccharides and other molecules that limit cell entrance by foreign bodies16,17. Not 
surprisingly, one of the major first-line anti-tuberculosis drugs, isoniazid, specifically 
targets synthesis of cell wall mycolic acids by targeting the M. tuberculosis enoyl 
reductase InhA18-20. Targeting the cell wall via an alternative mechanism, ethambutol is a 
first-line anti-tuberculosis drug with effects similar to those of isoniazid21. The remaining 
first-line anti-tuberculosis drugs are rifampicin and pyrazinamide which target the 
activity of RNA polymerase and, purportedly, fatty acid synthetase, respectively22-24.  
Drug regimens for individuals infected with M. tuberculosis typically require a 
treatment period of approximately 6 months25. Fluoroqunolones targeting M. tuberculosis 
DNA gyrase and injectable aminoglycosidases such as kanamycin and amikacin which 
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inhibit ribosome activity, are the major second-line anti-tuberculosis drugs currently used 
for treatment26,27. It is important to note that current anti-mycobacterial drugs almost 
exclusively target replicating mycobacteria resulting in extended periods of treatment in 
order to eradicate slower, non-replicating bacilli.  
Drug resistance  
 One of the major contributors to intrinsic M. tuberculosis antibiotic resistance is 
the activity of β-lactamases28. However, instances of multidrug-resistant TB (MDR-TB) 
and extensively drug-resistant TB (XDR-TB) can often times be attributed to case 
mismanagement and transmission within a particular community29. MDR-TB is defined 
by resistance to either of the common first-line drugs isoniazid or rifampicin while XDR-
TB refers to resistance to any fluoroquinolone and at least one injectable drug in addition 
to resistance to isoniazid or rifampicin1. In 2013 alone, MDR-TB accounted for an 
estimated 5% (480,000) of all TB cases around the world with almost half of those cases 
resulting in death1. Therefore, identification and characterization of novel therapeutic 
targets, and development of novel drugs and therapeutic strategies must be at the 
forefront of research endeavors seeking to reduce the global burden of the tuberculosis 
disease. 
PE/PPE Protein Family 
PE/PPE family overview 
 The PE/PPE family of proteins, named after a proline-glutamate (PE) or proline-
proline-glutamate (PPE) motif beginning at the ninth amino acid position, was discovered 
in the 1998 sequencing of the M. tuberculosis genome11. The N-termini of these protein 
families were highly conserved and the newly denoted proteins had previously been 
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implicated in antigenic variation prior to their reclassification30,31. PE and PPE proteins 
are made up of a 110 or 180 amino acid N-terminus, respectively, and, in some cases 
contain C-terminal extensions with a variety of functions11,32. The PE and PPE genes 
account for ~10% of the coding capacity of the M. tuberculosis genome, adding to the 
curiosity surrounding this relatively new family of proteins11. The number of identified 
PE and PPE genes varies slightly depending on the report with roughly 99 PE genes and 
68 PPE genes being reported11. 
 PE and PPE proteins are found in gene clusters throughout the M. tuberculosis 
genome. Several pieces of genomic, biochemical and structural data point to an important 
relationship between proteins of the two families. In some cases, PE and PPE proteins are 
present in operons where they are co-transcribed with their specific protein partner33. For 
example, PE25 (Rv2431c) and PPE41 (Rv2430c) can only be purified when co-
transcribed and co-purified in E. coli cells33. Until Strong et al. used this approach, the 
two proteins were only purified as aggregates suggesting that some PE and PPE protein 
pairs stabilize each other.  
 Structural data confirmed that some PE and PPE protein pairs interact. The crystal 
structure of the PE25-PPE41 complex revealed a ~100 Å extended heterodimeric alpha-
helical bundle33-35. EspG, a protein involved in secretion, was also crystallized with the 
PE25-PPE41 complex and shown to interact exclusively with PPE4134. The predicted 
corresponding EspG-binding sites of several other PPE proteins were used to create 
chimeras and test binding to EspG, revealing nanomolar affinity and implicating PPE 
proteins as containing the signal for secretion of the PE/PPE pair34.  
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Some PE and PPE genes are found adjacent to one another throughout the M. 
tuberculosis genome and sometimes interact with one another after expression for proper 
cellular localization and function33. However, many PE proteins can either be found 
clustered or dispersed throughout the genome33. Therefore, much evidence indicates that 
not all PE proteins have a cognate PPE partner and often times function alone. 
PE proteins and PE_PGRS (polymorphic GC-rich repetitive sequences) proteins 
 The polymorphic GC-rich repetitive sequence (PGRS) family was first described 
in 1995 with the consensus nucleotide sequence CGGCGGCAA at 26 M. tuberculosis 
loci30. However, it wasn’t until later when Cole et al. published the sequence of the M. 
tuberculosis H37Rv genome that the PE family of proteins was described and later 
separated into 3 subcategories that included the PE_PGRS subfamily11. The first type of 
PE protein was described as being comprised of the ~110 amino acid PE domain alone. A 
second subcategory of PE proteins is made up of the PE domain with an extended C-
terminal domain with a unique sequence and unknown function. For example, using an in 
silico sequence analysis, it was discovered that five proteins from this subcategory of PE 
proteins possess an α/β hydrolase fold indicating some sort of enzyme function36. It was 
later confirmed that one of those proteins does in fact possess esterase activity at its C-
terminus37.   
The majority of PE proteins, however, fall under the third subfamily of PE 
proteins called PE_PGRS proteins, which are characterized by an N-terminal PE domain 
and C-terminal PGRS region. The tandem repeats that make up the PGRS domain are 
Gly-Gly-Ala or Gly-Gly-Asn38. One piece of evidence points to the repeat sequences as 
acting as protectors of the PE_PGRS protein from proteosomal degradation and thus, 
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antigen processing by the host39. However, it does not appear that the PE_PGRS protein 
family adheres to the classical model of antigenic variation40. PE_PGRS proteins are 
mostly cell membrane and cell wall associated where they can be present on the cell 
surface at the host-pathogen interface38,41,42. The PGRS domain was also determined to 
be necessary for PE_PGRS33 localization to the mitochondria of eukaryotic cells and to 
induce apoptosis signifying a role for PE_PGRS proteins in pathogenesis43. 
PPE and PPE_MPTR (major polymorphic tandem repeats) proteins 
As with the PE_PGRS and the PPE families of proteins, the PPE_MPTR 
subgroup wasn’t discovered until 1998 with the sequencing of the M. tuberculosis 
genome11. Much like the PGRS protein family, the major polymorphic tandem repeats 
(MPTR) family of proteins was discovered several years before the discovery of the PPE 
protein family31. MPTRs, believed to be in approximately 80 regions of the M. 
tuberculosis genome, are made up of a consensus 10-nucleotide sequence 
(GCCGGTGTTG) separated by 5-nucleotide segments. 
Similar to the PE family, the PPE family can be broken down into several 
subgroups including the ~180 amino acid PPE domain alone, PPE_PPW which contains a 
PXXPXXW motif, PPE_SVP which contains a conserved GXXSVPXXW motif around 
the 350 amino acid position and the most abundant and well-studied PPE subgroup, 
PPE_MPTR11,44. Of the 68 or so PPE proteins, 23 belong to the PPE_MPTR subgroup40. 
PPE_MPTR proteins contain tandem copies of NXGXGNXG at their C-termini and 
similar to PE_PGRS proteins, it is generally accepted the PPE_MPTR proteins play a role 
in M. tuberculosis pathogenesis and, potentially, antigenic variation11. 
M. tuberculosis secretion overview 
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 M. tuberculosis possesses several export systems utilized for secreting numerous 
extracellular and cell wall-associated virulence factors from the cytosol to their final 
subcellular locations. In this section I discuss the Seca1 and Seca2 export pathways, the 
twin arginine translocation (TAT) pathway and the mycobacteria-specific type VII 
secretion pathways. Discussed are the components of each export pathway, the type of 
cargo that is exported by each system and the relevance of each system to mycobacterial 
pathogenesis. 
 
General Secretion Pathway (Seca1/Seca2) 
 One of the keys to the functions of PE and PPE proteins and their subgroups is 
their ability to be exported to the cell surface or extracellular space where they often 
times come into contact with the host cell. The general secretion pathway, also called the 
Sec export pathway is the most common means of exporting proteins across the cell 
membrane. The Sec pathway is conserved in all bacteria although it has been most 
thoroughly studied in E. coli. Twelve different proteins of the Sec export pathway are 
required for M. tuberculosis growth45. The preproteins exported by the general Sec 
pathway are recognized in an unfolded state45. They are recognized by the Sec pathway 
secretion machinery by an N-terminal signal peptide that is positively charged at the N-
terminus, possesses an uncharged polar C-terminus and 10-15 amino acid hydrophobic 
center46. After being exported across the cell membrane the signal peptide is cleaved at 
the uncharged, polar region, thus liberating a mature protein46.  
 The primary housekeeping SecA protein, SecA1, which acts as an ATPase that 
binds to Sec pathway cargo and pushes the preproteins through the Sec export machinery, 
is essential in M. tuberculosis45,47. The transmembrane pore through which Sec export 
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pathway machinery, SecYEG, is made up of 3 proteins: a large transmembrane protein 
(SecY), a clamp-like protein that stabilizes SecY (SecE) and a protein that improves 
export efficiency (SecG)45. The signal peptidase responsible for cleavage of most Sec 
export pathway substrates is LepB although a second signal peptidase exists. 
 Not surprisingly, the Sec export pathway is important for M. tuberculosis 
virulence. For example, important virulence-related lipoproteins that are exported by M. 
tuberculosis such as LpqH, LppX and LprG are dependent on the Sec export pathway. In 
addition to exporting virulence factors, the Sec export pathway is also responsible for co-
translational insertion of integral membrane proteins into the mycobacterial cell 
membrane. The FtsY receptor, required for all bacterial growth including M. tuberculosis, 
recognizes the signal recognition particle, SRP, of nascent integral membrane proteins. 
SecA assists in the export process and the SecYEG channel delivers the membrane 
protein to the membrane. This along with the other secretory functions is a clear 
indication of the significance and breadth of Sec export in M. tuberculosis. 
 A second accessory export pathway protein, SecA2, also exists in mycobacteria. 
Although its function is similar to that of SecA1, there are some key differences between 
the two proteins and, thus, the pathways. SecA2 is smaller than SecA1 by approximately 
21 kDa and only shares 50% sequence similarity to SecA147,48. Unlike the Sec export 
pathway, the accessory SecA2 export pathway exports proteins with and without the Sec 
signal peptide. For example, KatG, which activates the antimycobacterial pro-drug 
isoniazid and the superoxide dismutase, SodA both lack the Sec signal peptide49,50. Both 
proteins, however, are exported in a SecA2-dependent manner. Nevertheless, SecA1 and 
SecA2 also share some similarities. Both SecA1 and SecA2 use ATPase activity to 
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function. As it is understood today, the accessory SecA2 export pathway uses the same 
export components of the Sec export pathway, namely SecYEG, in order to transport its 
cargo outside the cell51.  
Twin Arginine Translocation Pathway 
 The twin arginine translocation pathway (TAT) is named after a motif found in an 
N-terminal signal peptide similar to that of the Sec export pathway. However, there are 
several distinctions between the Sec export and TAT pathways. One of the major 
distinctions between the signal peptide of TAT pathway preproteins and Sec export 
pathway preproteins is a S/TRRXFLK motif containing 2 consecutive arginine residues 
(twin-arginines) although evidence indicates that one arginine can be sufficient for TAT 
export of a small number of proteins52-54. In addition to the presence of the twin-arginine 
motif in the signal peptide, preproteins must be properly folded for recognition and 
export by the TAT export system, a clear deviation from the requirement of unfolded 
preproteins in the Sec export pathway55,56. In addition, the TAT system, although present 
in Gram-negative and Gram-positive bacteria is not present in all bacteria like its protein 
export pathway companion SecA57. 
 The TAT export system, because it exports folded preproteins, is made up of 
slightly different components from the Sec export pathway that can accommodate the 
structurally diverse cargo. Three transmembrane proteins, TatA, TatB and TatC, 
constitute the bulk of the TAT system machinery with TatB and TatC forming a 
preprotein-binding complex. A TatB-TatC complex is formed after both proteins 
recognize and bind the twin-arginine motif of the preprotein’s signal peptide with TatC 
being the primary binding protein58. TatA has been shown to forma a variety of 
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oligomers (130 kDa- 390 kDa) that are believed to make up the pore through which TAT 
cargo traverses the cell membrane59,60. It is recruited to the TatB-TatC-preprotein 
complex, interacting primarily with TatB, and the cargo is exported by means of the 
proton motive force58. In E. coli, LepB, the same signal peptidase used to cleave Sec 
export pathway peptide signals, liberates TAT preporteins from their signal peptides61. 
This function has been extrapolated to be present in the homologous LepB protein in M. 
tuberculosis. 
The M. tuberculosis TAT export system is essential and, to date, only 18 TAT 
export proteins have been identified in M. tuberculosis although several more likely 
exist45,62,63. Of these proteins with an experimentally determined TAT signal peptide, five 
(~28%) have been identified as required for virulence in M. tuberculosis45. Therefore, the 
TAT export system has been implicated in M. tuberculosis virulence. Also, a key β-
lactamase that helps protect the cell from damage by β-lactam antibiotics, BlaC, is 
exported via the TAT system64. Therefore, in addition to pathogenesis, the TAT export 
system plays a role in M. tuberculosis drug resistance. 
ESX-1 
ESX-1 is the best characterized Type VII secretion systems in M. tuberculosis. 
The ESX system derived its name from one of its substrates, ESAT-6, which, along with 
its heterodimeric partner CFP-10, are required for full M. tuberculosis virulence65. In 
cultured bacteria, the two proteins are found in the culture filtrate and have also been 
found to associate with the cell wall66,67. A general secretion motif, YxxxD/E, was 
discovered to be necessary for export of ESX-1-specific proteins including one of the 
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hallmark substrates of ESX-1, CFP-10, the virulence-associated protein EspB, and some 
PE proteins68. This motif is absent in PPE proteins and ESAT-6-like proteins.  
 ESX-1 is also the best-characterized export system in terms of its architecture. 
The genes comprising the ESX-1 export system are found in the esx-1 gene locus of M. 
tuberculosis. Interestingly, the esx-1 gene locus is absent in the attenuated M. bovis BCG 
vaccine strain as it is part of the region of difference (RD1), which is missing in M. bovis 
BCG69. This is the earliest and, perhaps, strongest piece of evidence indicating an 
essential role of the ESX-1 system in M. tuberculosis virulence. The proteins located in 
the esx-1 gene locus that constitute the ESX-1 secretion machinery include one 
membrane-bound serine protease (MycP1), two cytosolic ATPases (EccA1 and EccCb1) 
and four membrane associated proteins (EccB1, EccCa1, EccD1, and EccE1)45,70.  
MycP1, a subtilisin-like protease, cleaves ESX-1 substrates after export to the cell 
wall whereas EccA1 and EccCb1 interact with the C-terminus of ESX-1 substrates on the 
cytosolic side of the cell membrane and use their ATPase activity to assist 
translocation45,70-72. It is generally accepted that EccD1, a protein with 11 membrane-
spanning helices, forms the channel through which ESX-1 substrates pass whereas the 
remaining membrane proteins play a more peripheral role interacting with ESX-1 
machinery45,70,73. 
ESX-3 
To date, there is limited information regarding the ESX-3 secretion system. Using 
an esx-3 conditional knockout, Serafini et al. discovered that growth of cultured M. 
tuberculosis could be restored when the media was supplemented with iron and zinc74. It 
was also discovered that ESX-3 is essential for cultured M. tuberculosis growth74. 
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Although many of the genes encoded in the esx-3 gene locus remain to be identified, it 
has been suggested that the ESX-3 system secretes factors such as the EsxG-EsxH 
complex that assists in regulating metal uptake by M. tuberculosis74-76. One group 
demonstrated that scavenging of iron via the M. tuberculosis mycobactin pathway 
requires the presence of ESX-3, further highlighting the importance of the export system 
in M. tuberculosis growth77. Although there has been some success with regards to 
elucidating the role of ESX-3 export in M. tuberculosis, the genes comprising specific 
components of the ESX-3 export machinery remain to be identified. 
ESX-5  
 The ESX-5 secretion system is specific to slow growing mycobacteria including 
members of the M. tuberculosis complex (MTC), M. tuberculosis, M. africanum, and M. 
bovis78. Most research centered on ESX-5 has used M. marinum as a model. However, 
Bottai et al. were able to directly study the role of M. tuberculosis ESX-5 in protein 
export and virulence by creating mutants lacking proteins from the ESX-5 locus79. These 
studies showed that ESX-5 in M. tuberculosis is a functional secretion system that is 
important for maintenance of cell wall stability and virulence. ESX-5 is responsible for 
exporting a number of PE and PPE proteins to the cell surface and extracellular space 
including all of the PE_PGRS proteins in M. marinum (not confirmed in M. 
tuberculosis)80. Many PE proteins with roles in virulence are exported by ESX-5. The 
PE/PPE heterodimer, PE25-PPE41, is one example of a PE/PPE pair with a role in 
virulence exported by ESX-533,68,81. Other PE_PGRS and PPE_MPTR proteins identified 
in M. marinum are also exported by the ESX-5 system80. 
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 There is no crystal structure of the ESX-5 export machinery. However, there have 
been some efforts to characterize the architecture of the ESX-5 membrane complex of M. 
tuberculosis using M. marinum and M. bovis BCG as model organisms. The five genes 
comprising the ESX-5 export system are located in the esx-5 gene locus and named 
EccA5, EccB5, EccC5, EccD5, EccE5 for ESX-conserved component82,83. The subscript ‘5’ 
refers to these proteins comprising the machinery of the ESX-5 system as opposed to the 
four remaining ESX systems. EccC5 and EccD5 are both believed to make up the 
membrane channel for translocation of substrates because of their essentiality in ESX-5 
dependent secretion82. In addition, EccC5 has three predicted nucleotide-binding domains 
and shares homology with the FtsK/SpoIIIE ATPase family82. Therefore, it is likely that 
EccC5 uses rounds of ATP hydrolysis to help translocate ESX-5 substrates across the cell 
wall82. EccB5, EccC5, EccD5 and EccE5 all make up a 1,500 kDa protein complex that 
localizes to the cell wall while EccA5 is not associated with the cell wall or insoluble 
fractions in experiments exploring ESX-5 architecture82. It is likely that EccA5 interacts 
with ESX-5 substrates and/or the cytosolic portion of the ESX-5 membrane complex. 
EccB5 and EccE5 likely play a peripheral role helping to stabilize the remainder of the 
EccBCDE complex for efficient translocation of ESX-5 substrates. 
Although ESX-5 substrates lack Sec and TAT signal peptides, a general motif at 
the N-terminus of PE proteins, YxxxD/E, is required for ESX-5 dependent secretion68. It 
has also been demonstrated that some ESX-5 substrates are proteolytically cleaved upon 
export68,84,85. The PE_PGRS protein, LipY, was the first PE protein with an 
experimentally determined enzymatic function and its export to the cell wall has been 
thoroughly characterized. LipY is composed of an N-terminal PE domain containing a 
 14 
 
YAAAE secretion motif and a C-terminal lipase domain capable of hydrolyzing long 
chain triglycerides68,86. LipY’s PE domain is cleaved between a glycine and alanine upon 
export indicating that the PE domain acts a pseudo-secretion signal for export via ESX-
585. However, it does not appear all ESX-5 substrates are proteolytically processed 
although this cleavage feature does appear to be one of the many putative functions of the 
ESX-5 system. In addition, some PE and PPE proteins such as PE25 and PPE41 are 
exported as obligate-heterodimers by ESX-5 and depend on a YATAE secretion motif in 
PE2533,68. Some structural data suggest that the YxxxD/E motif of the PE domain of PE 
proteins may interact with the PPE domain of its associated PPE protein although 
PE/PPE complex formation does not appear to be a prerequisite for all ESX-5 
substrates68,70. Taken together, biochemical, structural, and functional studies indicate 
that PE proteins contain an export motif that can, in some cases, direct the export of a 
partner protein from the M. tuberculosis cytosol. 
Role of Lipids and Mycobacterial Lipases 
Mycobacterium Tuberculosis Lipid Metabolism 
 The glycoxylate cycle is a key metabolic process for providing M. tuberculosis 
with energy during pathogenesis87. Isocitrate lyase, an essential enzyme in the glyoxylate 
cycle that converts isocitrate to glyoxylate and succinate which is converted into energy 
in the tricarboxylic acid cycle, is upregulated under minimal growth conditions such as 
acetate and low oxygen88,89. The glyoxylate cycle, however, begins with acetyl coenzyme 
A (acetyl-CoA), which is a product of β-oxidation. Beta-oxidation involves the catabolic 
processing of fatty acids derived from lipids such as triacylglycerols (TAGs). Therefore 
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processing of lipids into free fatty acids represents the initial step for β-oxidation and 
ultimately energy production for M. tuberculosis, especially during dormancy.  
 Based primarily on sequence identity, M. tuberculosis H37Rv is believed to have 
approximately 250 genes involved in lipid metabolism11. Some of these genes encode 
enzymes such as TAG synthetases, fatty acid synthases and numerous serine hydrolases  
including lipases (Fig 1). One of the critical reasons why M. tuberculosis possesses such 
a large number of lipid metabolism-related genes, many of which are  
redundant, is because of its complex, lipid-rich cell wall11. Synthesis of the major cell 
wall component, mycolic acids, requires a number of biosynthetic steps. The M. 
tuberculosis cell wall is key to its drug resistance and is the target of the first-line 
tuberculosis pro-drug isoniazid which specifically targets the synthesis of cell wall 
mycolic acids after being activated by the katG gene19,50,90. Unfortunately, isoniazid only 
targets actively replicating M. tuberculosis, not dormant bacilli.  
 Unlike the lipids that make up the cell wall, intracellular lipids, specifically TAGs, 
are key to fueling M. tuberculosis metabolic processes. Lipid droplets containing mostly 
cholesterol and TAGs can be found in M. tuberculosis grown in vitro as well as in 
samples of sputum from patients classified as having clinical tuberculosis91. Host foamy 
macrophages loaded with lipid droplets contain M. tuberculosis bacilli and provide a 
means for the bacteria to accumulate TAGs. It is known that M. tuberculosis accumulates 
TAGs during dormancy; several lipid metabolism genes are upregulated during dormancy 
and that the lipids within the bacilli are derived from host cell lipids86,92,93. This evidence 
points to TAG lipases having a direct role in the accumulation and utilization of lipids for 
M. tuberculosis energy. 
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Figure 1. Activity-Based Protein Profiling of Several Fractions of M. tuberculosis. 
Serine hydrolases present in the indicated fractions of M. tuberculosis were probed using 
the fluorescent TAMRA-FP Serine Hydrolase probe for 30 minutes at room temperature, 
Reactions were quenched with SDS-loading dye and samples were boiled for 10 minutes 
at 100°C. Samples were resolved using SDS-PAGE and imaged using a Typhoon imager. 
(+ and – indicate boiled and unboiled samples, respectively, prior to reaction with the 
activity-based probe)  
  
 
 
TAMRA FP-Serine hydrolase probe 
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Lipases 
 Lipases are enzymes that catalyze the hydrolysis of lipids to free fatty acids. 
TAGs, which are made up of a glycerol backbone and three fatty acids, are hydrophobic 
energy-possessing molecules that can be mobilized by TAG lipases. TAG lipases 
specifically hydrolyze the fatty acid of TAGs at the sn1 or sn3 (terminal) positions 
yielding diacylglycerol and one free fatty acid although some reactions result in cleavage 
of two free fatty acids, one from both the sn1 and sn2 positions. Therefore, TAG lipases 
represent the rate-limiting enzymes in mobilizing free fatty acids for energy use.   
 Lipases belong to the superfamily of enzymes called serine hydrolases, which are 
characterized by a nucleophilic serine residue in a loop region flanked by glycine 
residues94. A histidine residue and either aspartate or glutamate residue make up the 
remainder of the catalytic triad which behaves as a charge relay system to activate the 
serine residue95. Structurally, TAG lipases have an α/β hydrolase fold characterized by 
alternating beta strands and alpha helices forming a unique α/β sheet95. A hydrophobic 
pore leading to the active site accommodates the lipid substrate. A lid domain, usually 
made up of one or two α-helices controlled by a hinge-like function, helps direct substrate 
specificity by presenting a hydrophobic surface for contact with the lipid96. Exchanging 
of lids from different lipases can result in a difference in relative specific activity, 
implicating lipase lids as crucial structural components for enzymatic activity97. 
Bacterial Lipases 
 Lipases have been implicated in the virulence and biofilm formation of bacteria. 
In Stapylococcus aureus, deletion of the lipase-encoding gene led to a reduction in 
biofilm formation in vitro and a decreased bacterial load in the liver, kidney and spleen of 
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infected mice98. It has also been more directly demonstrated that bacterial lipases have 
play a role in altering the host immune system in order to more effectively cause 
infection. Independent of enzymatic activity, Staphylococcal lipase had a protective 
effect on bacterial phagocytosis by granulocytes99. The presence of Staphylococcal lipase 
also immobilized granulocytes and drastically altered the morphology of granulocytes 
proving bacterial lipases have a direct role in the infection process99. Therefore, 
expanding the biochemical and structural information concerning bacterial lipases is of 
utmost importance to targeting such pathogens for therapeutic discovery and 
development. 
LipY 
Regulation during dormancy and regrowth 
LipY, like many genes believed to be involved in lipid metabolism, is upregulated 
during the M. tuberculosis dormancy phase86. Deb et al. demonstrated this by measuring 
expression of the 24 putative lipase genes including LipY in M. tuberculosis grown under 
dormancy-like conditions86. Deb et al. also demonstrated that LipY is the major 
contributor to M. tuberculosis lipase activity in vitro and that its enzymatic activity is 
upregulated during dormancy86. It also appears that LipY is important for breaking down 
stored TAGs within M. tuberculosis during regrowth from dormancy100. A knockout 
mutant of the M. bovis BCG LipY ortholog had a negative effect on the amount of stored 
TAGs, rate of bacterial regrowth and lipase activity during the first day of regrowth100. 
Although LipY appears to be upregulated during the dormancy phase and a key player in 
regrowth of M. tuberculosis during the regrowth phase, the specific factors that regulate 
expression of LipY are not yet known.  
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Subcellular location 
 Several groups have attempted to elucidate the precise subcellular location of 
LipY. The initial report describing LipY’s biochemical and enzymatic properties 
demonstrated that LipY hydrolyzes TAGs intracellularly86. A later study used 
immunoblot analysis to demonstrate that M. tuberculosis-LipY overexpressed in M. bovis 
BCG could be detected both in the cytosol and cell wall101. Mishra et al. also 
demonstrated that the absence of LipY’s PE domain (LipYΔPE) did not impact its 
subcellular localization. Furthermore, it was demonstrated using electron microscopy that 
LipY and LipYΔPE are located on the outer most surface of the M. bovis BCG cell wall. 
Similarly, it was demonstrated by Daleke et al. that LipY is exported to the cell wall of M. 
marinum by immunoblot analysis. Daleke et al. also demonstrated that LipY is 
responsible for the extracellular hydrolysis of a lipid-like substrate when incubated with 
intact M. marinum cells expressing the enzyme85. Although Daleke et al. provided 
evidence that supported the idea of LipY being exported to and localized on the cell wall, 
the group also demonstrated that LipY’s PE domain is necessary for export via the type 
VII secretion system, ESX-585. This contrasts with evidence from Mishra et al. that 
demonstrated that LipY is localized to the cell wall in the presence or absence of its PE 
domain101. However, it wasn’t until 2012 that Daleke et al. showed that a general 
secretion motif (YxxxD/E) located in the PE domain of LipY and other ESX-5 substrates 
is required for export to the cell wall and extracellular space68.  
Purification of LipY 
 Purification of the 45 kDa lipase, LipY, has proven difficult over the last decade. 
In all attempts to purify the enzyme, denaturants such as 8 molar urea, detergents such as 
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N-lauroylsarcosine or both have been used to solubilize the protein because of its 
lipophilic nature and tendency to be found in inclusion bodies86,101-103. LipY has been 
expressed in both Escherichia coli and Mycobacterium smegmatis86,101-104. In some cases, 
a histidine tag is placed at the N-terminus of the protein and used for nickel affinity 
chromatography as a purification step86,101-104. However, LipY was subjected to further 
purification by gel filtration chromatography in only 2 cases86,102. In one case, LipY 
eluted near the void volume of the gel filtration column where it likely existed as a 
soluble aggregate while the elution profile of LipY was not presented in the other 
study86,102.  
Role of LipY’s PE Domain 
 The main function of LipY’s PE domain is likely as a non-typical secretion signal 
that is recognized by the ESX-5 secretion system68,85. Generally, the PE domain is 
described as being ~110 amino acids11. However, LipY’s PE domain has been described 
as being 99 amino acids101. This distinction agrees with evidence that the position of the 
YxxxD/E motif (YAAAE) responsible for export to the cell wall begins at position 88 
and ends at position 92 of the N-terminus68. It is unclear how the YxxxD/E motif targets 
proteins to the cell wall but it has been suggested that, based on the crystal structure of a 
different PE protein, the secretion motif may be recognized by the ESX-5 membrane 
complex35. Once exported to the cell wall, the LipY’s PE domain is proteolytically 
cleaved by an unknown mechanism between a glycine and alanine at positions 149 and 
150, respectively85. Therefore, although the PE domain has been described as being made 
up of the first 99 amino acids of LipY, the physiological cleavage site of the PE domain 
is much further away. In addition to acting as a non-traditional secretion signal, it has 
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also been implied that LipY’s PE domain is capable of regulating its lipase activity101. 
This result was demonstrated when Mishra et al. expressed full length LipY and a LipY 
mutant devoid of the PE domain (first 99 amino acids) in M. smegmatis and compared the 
hydrolase activity of increasing amounts of enzyme-containing cell wall fragments101. In 
the absence of the PE domain, there was a greater increase in LipY hydrolase activity 
compared to the full-length enzyme, which suggests that the PE domain is a 
downregulator of LipY activity. 
Substrate specificity and activity 
 In 2006, Deb et al. tested the effects of several different conditions on 
recombinantly expressed and purified LipY activity86. First, it was discovered that 
purified LipY has a preference for hydrolyzing long-chain TAGs (12-22 carbon fatty acid 
chain) in vitro by using a radiometric assay with triolein as a substrate. Triolein is a 
triglyceride composed of glycerol and oleic acid, an unsaturated 18-carbon fatty acid. 
LipY demonstrated Km and Vmax values of 7.57 mM and 653.3 nmol/mg/min, 
respectively. The optimal pH for LipY activity is between 8 and 9 while LipY appears to 
retain activity at temperatures near 60°C. The effects of sodium dodecyl sulfate (SDS) 
and non-ionic detergents Triton X-100 and Tween-20 on LipY were also explored. 4 mM 
SDS completely inactivates LipY activity while a slight increase in activity is observed 
when LipY is incubated with 0.1% Triton X-100 (v/v). Interestingly, Tween-20 abolishes 
LipY activity above 0.5% (v/v). The active site serine residue of LipY is present in a 
GDSAG motif at the C-terminus of the protein, a conserved motif characteristic of the 
hormone-sensitive family of lipase86. The residues comprising the catalytic triad of LipY 
include serine 309, aspartate 383, and histidine 413104.  
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LipY’s role in virulence 
 LipY has also been implicated in M. tuberculosis virulence. The only available 
vaccine for protection against tuberculosis, the M. bovis BCG strain, has been used to 
study the effect of overexpression of LipY on host protection105. Balb/c mice immunized 
with recombinant M. bovis BCG overexpressing LipY challenged with the virulent M. 
tuberculosis H37Rv strain leads to decreased survival compared to mice immunized with 
the wild type vaccine strain105. In addition, mice immunized with purified recombinant 
LipY and challenged with M. tuberculosis H37Rv experienced increased survival 
compared to non-immunized mice suggesting LipY can be used as an antigen to provide 
protection against M. tuberculosis infection105. These mice also experienced an enhanced 
IL-2, IL-6, IFN-gamma and TNF cytokine response compared to non-immunized mice105. 
When mice were immunized with M. bovis BCG overexpressing LipY, the same 
cytokines were enhanced but to a lesser extent than the cytokines of mice immunized 
with the wild type M. bovis BCG strain105. Therefore, LipY appears to play a role in the 
virulence of M. tuberculosis. 
 A second study on the role of LipY in M. tuberculosis virulence demonstrated 
similar results. Singh et al. discovered that overexpression of LipY in M. tuberculosis 
H37Rv results in weight loss, a significant increase in bacterial load in the lungs, damage 
to the lungs and spleen and decreased survival of approximately one week of infected 
mice compared to mice infected with wildtype M. tuberculosis H37Rv106. Immunization 
of mice with recombinant purified LipY prior to challenge with M. tuberculosis H37Rv 
overexpressing LipY led to an increased median survival of approximately 2 weeks 
compared to non-immunized mice demonstrating the ability of LipY to have a protective 
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effect against infection105. The ability of LipY overexpression in M. tuberculosis H37Rv 
to cause increased mortality in challenged mice is likely a result of the decreased 
cytokine response compared to uninfected mice and mice challenged with wildtype M. 
tuberculosis H37Rv as evidenced by decreases in IL-2, Il-6, IL-17, TNF, and IFN-
gamma105.  
Inhibitors against LipY 
 LipY has also been researched as a potential therapeutic target. The well-
characterized lipase inhibitor, tetrahydrolipstatin (THL), has been shown to be a potent 
inhibitor of M. tuberculosis growth and disrupt M. tuberculosis morphology102,107. A 
derivative of the compound oxadiazolone called MmPPOX was also tested for its 
inhibitory function against recombinant purified LipY as well as 8 additional putative M. 
tuberculosis lipases and M. tuberculosis and M. bovis BCG cells102. MmPPOX inhibited 
LipY with an apparent inhibitory constant (Ki) of 7.7 μM102. It was also demonstrated 
that MmPPOX inhibited M. tuberculosis and M. bovis BCG growth with potency 
comparable to that of THL and it was inferred that this effect comes as a result of 
inhibition of LipY and related lipases102. Screening of different inhibitors against LipY 
activity lead to synthesis of several compounds, one of which displayed a half maximal 
inhibitory concentration (IC50) value of 5.13 μM and very little cytotoxicity at high 
concentrations when tested against M. tuberculosis H37Rv suggesting their activities are 
specific to LipY104. 
 The work presented here lays a foundation for studying and better understanding 
the enzyme kinetics of established bacterial lipases as well as the activities of putative 
enzymes from the M. tuberculosis PE/PPE family of proteins. The need for an improved 
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purification method and more thorough characterization of LipY and its PE domain is 
also addressed in this work. Not only does this work improve our overall understanding 
of LipY and the function of its PE domain but it also gives us insight into how additional 
PE and PPE proteins may behave differently in the absence of their N-terminal domains. 
The difference in the activities of these enzymes with and without their associated 
domains may ultimately impact the mechanism in which they are inhibited and, 
subsequently, the manner in which they must be investigated.  
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CHAPTER 2: MODULATION OF THE ACTIVITY OF MYCOBACTERIUM 
TUBERCULOSIS LIPY BY ITS PE DOMAIN1 
Summary  
 Mycobacterium tuberculosis harbors over 160 genes encoding PE/PPE proteins, 
several of which have roles in the pathogen’s virulence. A number of PE/PPE proteins 
are secreted via Type VII secretion systems known as the ESX secretion systems. One PE 
protein, LipY, has a triglyceride lipase domain in addition to its PE domain. LipY can 
regulate intracellular triglyceride levels and is also exported to the cell wall by one of the 
ESX family members, ESX-5. Upon export, LipY’s PE domain is removed by proteolytic 
cleavage. Studies using cells and crude extracts suggest that LipY’s PE domain not only 
directs its secretion by ESX-5, but also functions to inhibit its enzymatic activity. Here, 
we attempt to further elucidate the role of LipY’s PE domain in the regulation of its 
enzymatic activity. First, we established an improved purification method for several 
LipY variants using detergent micelles. We then used enzymatic assays to confirm that 
the PE domain down-regulates LipY activity. The PE domain must be attached to LipY 
in order to effectively inhibit it. Finally, we determined that full length LipY and the 
                                                 
1A significant portion of Chapter 2 appeared in an article in PLOS One. The original 
citation is as follows:  
Garrett CK, Broadwell LJ, Hayne CK, Neher SB (2015) Modulation of the Activity of 
Mycobacterium tuberculosis LipY by Its PE Domain. PLoS ONE 10(8): e0135447. 
doi:10.1371/journal.pone.0135447 
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mature lipase lacking the PE domain (LipYΔPE) have similar melting temperatures. 
Based on our improved purification strategy and activity-based approach, we concluded 
that LipY’s PE domain down-regulates its enzymatic activity but does not impact the 
thermal stability of the enzyme. 
Introduction 
 Mycobacterium tuberculosis (Mtb) is remarkably adept at interfering with host 
cellular processes in order to evade destruction. This ability depends on the secretion of 
virulence factors that modify the host environment. One family of proteins, known as PE 
and PPE proteins, are involved in immune evasion and virulence43,108,109. PE/PPE 
proteins are unique to mycobacteria; they were initially discovered when sequencing of 
the Mtb genome revealed approximately 160 genes encoding proteins with Pro–Glu (PE) 
or Pro–Pro–Glu (PPE) motifs near their N-termini11. Subsequent analysis revealed that 
PE/PPE proteins comprise about 7% of the coding capacity of the Mtb genome110. 
Although PE/PPE domains have been identified in both pathogenic and saprophytic 
mycobacteria, pathogenic mycobacteria maintain the highest number of PE/PPE 
proteins111.  
 The PE motif is a moderately conserved, 110-residue domain found at the N-
terminus of PE proteins11. The PPE motif is a distinct, but also conserved, domain of 
about 180 residues found at the N-terminus of PPE proteins11. The C-terminal domains of 
both PE and PPE proteins are highly variable and can encode enzymatic domains, 
conserved sequence motifs or large, repeated arrays of peptide motifs11,110. Genes 
encoding PE and PPE proteins are often proximal on the Mtb genome and functionally 
linked112. In fact, structural studies show that in some cases, PE and PPE proteins form 
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heterodimeric complexes33. PE/PPE gene families co-evolved with specialized, type VII 
secretion systems important to Mtb virulence known as the ESX secretion systems113. 
The Mtb genome encodes five type VII secretion systems, named ESX-1 to ESX-551. 
Studies using both Mtb and Mycobacterium marinum revealed that several PE and PPE 
proteins depend on ESX-5 for export79,84.   
 LipY is a PE protein with a C-terminal triglyceride (TG) lipase domain86. LipY is 
proposed to have a dual role in Mtb pathogenesis106. First, Mtb is known to store host-
derived TGs in lipid droplets that provide fuel during reactivation from dormancy93,100,114. 
LipY is the primary contributor to the break down of these stored TGs86. Next, 
overexpression of LipY has been implicated in increased Mtb virulence as shown by the 
enhanced mortality of TB-infected mice106. The increased mortality associated with LipY 
overproduction is attributed to down-regulation of host immunity by the products of LipY 
TG hydrolysis99,106. These two roles for LipY are consistent with the observation that 
LipY is found both intracellularly and on the cell exterior85.  
 LipY lacks a classic secretion signal but contains an YxxxD/E motif (Y-A-A-A-
E) beginning at position 88 of its PE domain. The YxxxD/E motif is found in several 
other PE proteins and appears to be a general secretion signal required for recognition by 
the ESX-1 and ESX-5 secretion systems68. In LipY the motif is essential for secretion by 
ESX-568. In some ESX and PE/PPE protein pairs, the YxxxD/E motif in one protein 
forms a joint motif with the sequence WxG present in its partner70. However, there is 
little evidence to suggest LipY has a PPE binding partner necessary for secretion33,115.  
 Upon export to the cell wall, LipY’s PE domain is removed by proteolytic 
cleavage85. One study using the cell wall fraction of Mycobacterium smegmatis 
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containing LipY hinted that LipY’s PE domain could down-regulate its enzymatic 
activity101. This study also showed that mycobacteria expressing LipY lacking its PE 
domain exhibited a greater reduction in intracellular TG pools than mycobacteria 
expressing LipY. Therefore, it appears that although the Y-A-A-A-E motif in the N-
terminus of LipY is necessary for its export to the cell wall, the PE domain likely has 
additional, unexplored functions. Here, we utilize biochemical assays with purified 
proteins and determined that LipY’s PE domain regulates its enzymatic activity. 
Materials and Methods 
LipY, LipYΔPE and PE Domain Purification 
 LipY, LipYΔPE (amino acids 150-437) and the PE Domain (1-149) were cloned 
into pET16b expression vectors (Novagen) with a C-terminal His tag. The proteins were 
expressed in BL21 (DE3) E. coli cells and grown to an OD600 of ~0.7 at 37°C. Protein 
expression was induced with 0.7 mM isopropyl-beta-D-thiogalactopyranoside and cells 
were shaken at 18°C for 16 h. Cells were then pelleted at 5,900 x g for 25 min and the 
pellet suspended in buffer A (20 mM HEPES pH 7, 300 mM NaCl, 10 mM imidazole, 
10% glycerol) before being lysed in a Nano DeBEE Laboratory homogenizer (BEE 
International) at 20,000 psi. The lysates were cleared by centrifugation at 23,000 x g for 
40 minutes. The resulting pellet was resuspended in buffer B (20 mM HEPES pH 7, 300 
mM NaCl, 10 mM imdazole, 10% glycerol, 0.5% w/v N-laurylsarcosine) with agitation at 
4°C for 1 hour (incubation time is critical) followed by centrifugation at 23,000 x g for 40 
minutes. The supernatant was then incubated with pre-equilibrated nickel-nitrilotriacetic 
acid resin (Qiagen) with gentle agitation for 1 hour. The resin was washed with 4 column 
volumes of buffer A followed by elution with buffer C (20 mM HEPES pH 7, 300 mM 
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NaCl, 350 mM imidazole, 10% glycerol). Eluted protein was incubated with Tween 20 
with gentle agitation for 1 hour at 4°C and then loaded onto a pre-equilibrated Superdex 
200 10/300 HR gel filtration column (GE Healthcare) with Buffer D (20 mM HEPES pH 
7, 100 mM NaCl, 10% glycerol). Protein was eluted over 1 column volume with Buffer D. 
Protein that eluted between 8 and 10 mLs was collected and labeled ‘Peak 1’ while 
protein that eluted between 12 and 14 mL was labeled ‘Peak 2’. Protein was flash frozen 
in liquid nitrogen and stored at -80°C. A final purity of >95% was achieved for both 
LipY and LipYΔPE (S1 Fig). Because LipY and LipYΔPE were purified with detergent, 
we tested their ability to hydrolyze a natural triglyceride substrate in buffer that did not 
contain detergent and found that both were active (S2 Fig).   
Quantification of active LipY and LipYΔPE by activity-based protein profiling (ABPP)  
 LipY and LipYΔPE were diluted to the same concentration using ABPP buffer 
(20 mM Tris pH 8, 100 mM NaCl). A 1.5 molar excess of ActivX TAMRA-FP serine 
hydrolase probe (Thermo Scientific) was added to each sample and incubated for 30 
minutes. The reactions were quenched with addition of SDS loading dye and boiling for 
10 minutes. To quantitate the amount of active protein, a standard of the probe alone was 
prepared by serial dilution with ABPP buffer. All samples were resolved using SDS-
PAGE and imaged using a Typhoon Trio+ imager (GE Healthcare Life Sciences). 
ImageQuant TL software was used for quantification of bands corresponding to the 
TAMRA-FP serine hydrolase probe alone, probe-labeled LipY and probe-labeled 
LipYΔPE. 
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Enzymatic Assays 
 Michaelis-Menten kinetics were measured as previously described116. Briefly, 
LipY or LipYΔPE was diluted in assay buffer (20 mM Tris pH 8, 150 mM NaCl, 0.2% 
Fatty acid free BSA, and 0.4% (v/v) Triton X-100) to a set concentration according to 
quantification by ABPP. Next, the fluorogenic substrate 1,2-Di-O-lauryl-rac-glycero-3-
(glutaric acid 6-methylresorufin ester) known as DGGR (Sigma Aldrich) was added. 
Substrate hydrolysis was measured by monitoring fluorescence with a 529 nm excitation 
wavelength and reading emission at 600 nm with a 590 nm cutoff filter over 30 minutes 
at 37°C. Non-enzymatic hydrolysis was subtracted and initial rates of hydrolysis were 
calculated using the first 10% of data. Initial rates were plotted against substrate 
concentration and fitted to the Michaelis-Menten equation using KaleidaGraph software.  
Circular Dichroism Measurements 
 Thermal stability assays were measured as previously described with some 
modifications117. Briefly, LipY or LipYΔPE was diluted to 10 μM in Buffer D and data 
were collected at 20°C. Molar ellipticity of thermal denaturation was monitored at 222 
nm from 4-90°C. Buffer D was used as a blank and all data were converted to mean 
residue ellipticity (MRE) using eq 1, where Θ is MRE, signal is the CD signal, C is the 
protein concentration (mM), n is the number of amino acids and l is the cell path length 
(cm)118.  
                                      Θ = (100 × signal) ÷ (C × n × l)                                (1) 
 
 
 
 31 
 
Results 
Detergent Separates Lipy into 2 Distinct Peaks 
 Most PE/PPE proteins do not have well-characterized functions, but LipY is a 
well-characterized lipase. We therefore used LipY to determine how the PE domain 
affects its enzymatic activity. To carry out these studies we first needed to resolve the 
oligomeric state of active LipY. Although LipY is a 45 kDa protein, previous reports of 
its purification show that it elutes from a gel filtration column at or near the void volume, 
indicating a protein of over 600 kDa86. LipY purified from this void fraction exhibited 
TG hydrolysis activity and in a previous study was used for its biochemical 
characterization86. We developed an improved purification protocol in which LipY 
migrates in the included volume of a Superdex 200 gel filtration column (Fig 2A, gray 
trace). To achieve this, we utilized detergent micelles to help solubilize nickel-purified 
LipY. Lipases function at the lipid-water interface, and they are frequently purified and 
crystallized in the presence of detergent micelles119,120. After addition of Tween 20 
(CMC= 0.6 mM) at a 270-fold molar excess over LipY, we observed that LipY elutes 
from a size exclusion column in 2 distinct peaks: one is in the void volume (Peak 1) and 
one in the included volume (Peak 2). By contrast, when LipY was not supplemented with 
detergent, only Peak 1 was observed (Fig 2A, black trace). We next tested the contents of 
both peaks by Western blot. These experiments confirmed that LipY migrates mainly in 
Peak 1 in the absence of Tween 20 but migrates in Peak 2 when Tween 20 is added (Fig 2, 
inset).  
 This result raised the question of whether LipY was migrating independently or 
in/on the detergent micelles. We next ran a sample containing only Tween 20 micelles on 
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the size exclusion column (Fig 2B). This trace revealed that LipY from Peak 2 matched 
the elution profile of the Tween 20 micelles. Next, we wanted to determine if the protein 
in Peak 1 was refractory to solubilization by detergent. We supplemented LipY isolated 
from Peak 1 with Tween 20, repeated the purification strategy using gel filtration and 
observed both Peak 1 and Peak 2 in the elution profile (Fig 2B, black trace). The 
appearance of LipY in both peaks was confirmed via immunoblot analysis. Taken 
together, these results indicate that Tween 20 micelles can extract LipY from a large, 
soluble aggregate. 
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Figure 2. Size Exclusion Chromatography of Lipy With or Without Tween 20. 
(A) LipY purified via Nickel affinity chromatography was resolved on a Superdex 200 
gel filtration column with (gray trace) or without (black trace) pre-incubation with a 270 
fold molar excess of Tween 20. In the presence of detergent a second peak in the 
included volume appears whereas a single peak in the included volume is observed when 
no detergent is present. (B) LipY purified in the void volume (Peak 1) was pre-incubated 
with a 270 fold molar excess of Tween 20 and subjected to size exclusion 
chromatography (black trace). This trace is overlayed with a trace of 6 mM Tween 20 
alone (gray trace). Western blots against the His tag of LipY were used to detect the 
presence of protein eluted from the gel filtration column in each experiment. 
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The PE Domain of Lipy Contributes to Formation of Lipy Aggregates in Peak 1 
 We next sought to determine whether the PE domain of LipY or the mature lipase 
(LipYΔPE) is responsible for LipY aggregation. On one hand, PE proteins are known to 
form dimers with their cognate PPE partner for recognition and exportation by unique 
type VII secretion systems33,121. Conversely, there are many examples of bacterial lipases 
that are prone to aggregation upon purification120,122. To answer this question, we first 
expressed and purified recombinant LipYΔPE (residues 150-437) and recombinant PE 
domain (residues 1-149) using nickel affinity chromatography. Consistent with the 
purification of LipY, we added Tween 20 at a 270 fold molar excess over protein to help 
solubilize the purified proteins prior to size exclusion chromotography. The elution 
profile for the PE domain revealed the formation of two distinct peaks as we previously 
observed with full length LipY (Fig 3). However, the elution profile of LipYΔPE featured 
a distinct peak in the included volume with a smaller, broad peak in the void volume. 
Immunoblot analysis of the size exclusion column fractions of LipYΔPE and the PE 
domain revealed that the majority of purified PE domain is in the void volume (Peak 1) 
whereas the majority of purified LipYΔPE is in the included volume (Peak 2). The data 
show that removal of the PE domain from purified LipY dramatically reduces its 
aggregation into Peak 1. Taken together with data from Figure 2, these results 
demonstrate that the PE domain drives the aggregation of LipY. 
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Figure 3. The PE Domain Contributes to Lipy Aggregation in vitro. 
LipYΔPE and the PE domain were resolved on a Superdex 200 gel filtration column. 
Both proteins were pre-incubated with a 270 fold molar excess of Tween 20 for 1 hour 
prior to being resolved on the column. In the gray PE domain trace, Peak 1 (~9.5 mL) 
elutes near the void volume and Peak 2 (~13 mL) elutes in the included volume. In the 
black LipYΔPE trace, a weak A280 signal was observed between 9 and 12 mL and a 
single distinct peak (Peak 2) elutes in the included volume. Western blots against the His 
tag of each construct show that the majority of the PE domain elutes in the void volume 
while the majority of LipYΔPE elutes in the included volume. 
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Lipy from Peak 2 is More Active Than Lipy from Peak 1 
 Although LipY from Peak 1 elutes in the void as a high molecular weight 
aggregate, our lab and others have observed that the LipY purified from Peak 1 maintains 
lipase activity86. We therefore set out to compare the fraction of active LipY purified in 
Peak 1 and Peak 2. First, we used activity-based protein profiling (ABPP) to measure the 
amount of active enzyme in both Peak 1 and Peak 2. In this method, the reactive 
fluorophosphonate group of the activity-based probe (ABP) forms a covalent bond with 
the active site serine residue of active serine hydrolases, including lipases with a 1:1 ratio 
of ABP:active site123. We calculated the amount of active enzyme in each peak (plotted in 
Fig 4A). LipY in Peak 2 contains more active enzymes (~45% active) than Peak 1 (~32% 
active). We then compared the Michaelis-Menten kinetics of LipY from Peak 1 and Peak 
2 using the long-chain lipase substrate DGGR (Fig 4B). These experiments confirmed 
that LipY in Peak 2 (Vmax= 3.2 ± 0.3 RFU s-1 pmol-1 total LipY) contains more active 
enzyme molecules than LipY in Peak 1 (Vmax= 2.5 ± 0.2 RFU s-1 pmol-1 total LipY). The 
Km values for Peak 1 and Peak 2 are within the experimental error of each other (5.0 ± 
1.5 and 4.8 ± 1.1 μM, respectively). However, when comparing the enzyme kinetics of 
equal amounts of active LipY from Peak 1 and Peak 2 based on our ABPP measurement, 
we observed almost no difference in the Vmax (S3 Fig). As a result, we concluded that 
although LipY from Peak 2 to contains more active enzymes than LipY from Peak 1, the 
enzymes from both fractions are catalytically equivalent. 
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Figure 4. There are More Active Lipy Molecules in Peak 1 Compared to Peak 2. 
(A) Equal concentrations of total LipY Peak 1 and Peak 2 were incubated with a 1.5 
molar excess of TAMRA-FP serine hydrolase probe for 30 minutes at room temperature. 
A standard was created using the probe alone. The amount of active Peak 1 and Peak 2 
were calculated based on the standard curve. (B) Bar graph showing the Vmax and Km 
from Michaelis-Menten curves comparing equal amounts of total LipY from Peak 1 and 
Peak 2 using the DGGR substrate. Error bars represent the standard error of the mean of 
6 independent measurements124. 
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 To confirm that Peak 2 is more active than Peak 1 we used an established method 
to compare the activities of the two peaks125. We used a separate protein purification as 
we observed that the exact fraction of active protein in each peak varied from purification 
to purification but Peak 2 was always more active than Peak 1. Tetrahydrolipstatin (THL) 
is a lipase inhibitor that covalently modifies the active site of lipases126,127. LipY (5 nM) 
was titrated with increasing concentrations of THL, and the residual lipase activity was 
compared to untreated LipY. Residual LipY activity was measured using the small, 
soluble substrate p-Nitrophenyl butyrate (pNPB) at a concentration of 200 μM, which is 2 
fold over the Km for LipY hydrolysis of pNPB. Consistent with data shown in Figure 4, 
LipY in Peak 2 is more active than LipY in Peak 1 (S4 Fig). Protein purified from Peak 2 
was used in all subsequent experiments as our studies show that it is the disaggregated, 
more active form of the enzyme.  
Lipyδpe is More Active Than Lipy 
 A study comparing cells expressing LipY vs. LipYΔPE reported that the crude 
cell wall fraction from the LipYΔPE-expressing cells had greater enzymatic activity101. 
These results suggest that the PE domain may down-regulate LipY enzymatic activity. 
However, because this result was obtained using a crude cell wall fraction, it could also 
be explained by loss of an inhibitor-binding site as a result of the deletion of the PE 
domain. Additionally, the authors created the initial LipYΔPE construct by deleting the 
first 99 residues from LipY’s N-terminus. Subsequently, experimental evidence showing 
the precise cleavage site (after glycine 149) for removal of the PE domain emerged85. We 
tested the role of the PE domain in LipY activity by comparing full length LipY and 
LipYΔPE generated using the physiological cleavage site. To compare the activities of 
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LipY and LipYΔPE, we first employed the method used in Figure 4A to calculate the 
amount of active protein. After determining the amounts of active LipY and LipYΔPE 
using the ABPP method, we compared Michaelis-Menten kinetics of equal amounts of 
active protein using DGGR as a substrate. These data show that LipYΔPE is more active 
than LipY, as shown by the representative plot in Figure 5A. Analysis of multiple data 
sets revealed Vmax values of 6.3 ± 0.8 and 11.3 ± 1.3 RFU s-1 pmol-1 for LipY and 
LipYΔPE, respectively, indicating a significant difference in activity (p<0.015) between 
the two LipY variants (Fig 5B, left graph). Loss of the PE domain does not affect 
substrate binding, as the Km values are equivalent for LipY and LipYΔPE (Fig 5B, right 
graph). 
 As shown in Figure 3, we successfully expressed and purified the 149-amino acid 
PE domain of LipY. We tested the ability of the purified PE domain to act as an inhibitor 
of LipYΔPE in trans. Increasing amounts of PE domain were incubated with a constant 
amount of LipYΔPE for 10 minutes prior to testing lipase activity. The initial velocity 
was plotted against substrate concentration and data for each concentration of PE domain 
tested were fitted to the Michaelis-Menten equation. We observed negligible differences 
in activity of LipYΔPE alone and LipYΔPE pre-incubated with PE domain (Fig 5C). This 
lack of inhibition indicates that the PE domain only inhibits LipY when it is part of the 
same molecule.  
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Figure 5. Lipy’s PE Domain Downregulates its Enzymatic Activity. 
(A) Equal amounts of active LipY and LipYΔPE as determined by ABPP were used to compare 
the Michaelis-Menten kinetics of the two constructs. Hydrolysis of the lipase substrate, DGGR 
was monitored at 37°C. Initial velocities for a representative data set were fit to the Michaelis-
Menten equation and plotted against substrate concentration. (B) Analysis of multiple data sets 
reveals that LipYΔPE has a Vmax that is approximately two fold higher than the Vmax for LipY 
(left graph). However, the Km is not affected (right graph). Error bars represent the standard error 
of the mean of 6 independent measurements124. “*” corresponds to p<0.015 of the Vmax of LipY 
compared to LipYΔPE. (C) LipYΔPE was titrated with 0, 10 or 100 nM PE domain and 
incubated for 10 minutes before testing its residual lipase activity as described in (A). 
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The PE Domain Does Not Affect Thermal Stability of Lipy 
 Finally, we asked if the PE domain might affect the thermal stability of full length 
LipY. We probed the thermal stability of both LipY and LipYΔPE by measuring their 
thermal denaturation using circular dichroism (CD) spectroscopy. Based on far-UV CD 
scans of both proteins, we elected to measure unfolding at 222 nm. Both constructs 
showed a single thermal unfolding transition. Furthermore, the melting temperatures (Tm) 
of the two constructs were very similar (Fig 6). Both constructs had Tms near 75°C, 
which suggests that even in the absence of the PE domain LipY is highly stable. This is in 
good agreement with a previous study measuring the activity of LipY as a function of 
temperature. In this study LipY retained partial activity even after incubation at 60°C for 
15 minutes prior to an activity assay86.    
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Figure 6. LipY and LipYΔPE Share Similar Thermal Unfolding Profiles. 
CD temperature scans of LipY (black) and LipYΔPE (gray) monitored at 222 nm 
between 25 and 95°C. Data points were collected every 1°C.  
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Discussion 
 PE and PPE proteins of Mtb were first described almost 17 years ago, and their 
molecular functions are still not fully understood. Studies with individual PE/PPE 
proteins suggest that they serve to target their C-terminal cargo to the type VII secretion 
systems85,128,129. However, the physiological utility of employing a large, aggregation 
prone domain to target proteins for secretion is not clear, and it is tempting to speculate 
that the PE domain may have additional roles. LipY represents one of the best candidates 
for studying the PE domain because its enzymatic activity is well established and the 
cleavage site for the PE domain is known. In the case of LipY, the PE domain has at least 
two distinct functions. First, it is clear that the YxxxD/E motif acts as a secretion signal 
for export of the mature lipase to the cell wall68. Second, the PE domain has been 
implicated as a regulator of enzyme activity101. Here, we utilize biochemical assays to 
investigate this observation because experiments initially describing this regulatory 
function were carried out using crude cell wall fraction. Thus, it is possible that other 
factors interacted with the PE domain to regulate LipY activity. Furthermore, only the 
first 99 amino acids were removed from LipY, as it was only later demonstrated that the 
PE domain precedes a linker region and the physiological cleavage site is after amino 
acid position 14985.  
 We therefore compared the lipase activity of purified LipY and LipYΔPE 
generated using the physiological cleavage site. We first needed to de-aggregate LipY 
and did so by utilizing Tween 20 detergent micelles. These experiments led to the finding 
that the PE domain of LipY provides an interface for its aggregation, as the isolated PE 
domain aggregated whereas LipYΔPE was less susceptible to aggregation. Our data 
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imply that PE proteins, especially those associated with the cell wall of Mtb, are prone to 
aggregation via their PE domain. This should be taken into consideration when purifying 
proteins from this family. We next quantified the amount of active enzyme molecules 
using an activity-based method to compare equal amounts of active LipYΔPE and LipY. 
We observed a clear increase in the maximum reaction velocity of purified LipYΔPE 
compared to LipY thus confirming that the PE domain does indeed down-regulate LipY 
activity. Finally, we added the isolated PE domain back to LipYΔPE and found that it did 
not inhibit in trans.  
 Thus, the PE domain must be attached to the mature lipase in order to inhibit 
lipase activity. It is likely that this connection is necessary because it increases the local 
concentration of the PE domain at the site of inhibition. In data not shown, we tested PE 
domain concentrations up to 0.5 μM but were not able to test higher concentrations due to 
the risk of PE domain aggregation. Our kinetic analysis shows that LipY has a lower Vmax 
and an equivalent Km as compared to LipYΔPE. This is characteristic of noncompetitive 
inhibition, in which an inhibitor affects enzyme activity by binding to a site other than the 
substrate-binding site (for example an allosteric site)130. However, understanding the 
precise molecular mechanism by which the PE domain reduces LipY activity will require 
further mechanistic studies.  
 Our study includes a useful technical advance. We used three different methods to 
compare the activities of LipY from Peak 1 and Peak 2: ABPP, active site titration using 
THL, and Michaelis-Menten kinetics using a model triglyceride substrate. All methods 
demonstrated that LipY from Peak 2 was more active than LipY from Peak 1. Generally, 
ABPP has been used as a proteomics tool for screening inhibitors and identifying 
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enzymes of interest in cell fractions131. Our study shows that the TAMRA-FP serine 
hydrolase activity based probe is also useful to quantify enzyme active sites. Because the 
ABPs only label active protein, this approach offers a quicker, easier way to quantitate 
enzyme active sites than using pre-steady state kinetics or active site titration.  
 LipY functions both intracellularly and extracellularly, and the PE domain is 
removed upon secretion85. Our data suggest that the absence of the PE domain allows the 
mature lipase to better hydrolyze TGs outside the cell, thus tuning LipY activity to its 
environment. The observations that the PE domain reduces LipY activity leads to the 
question of whether this is a LipY-specific phenomenon or a common occurrence. 
Currently, few other PE/PPE proteins have known enzymatic functions. It is also not well 
established if other PE/PPE domains are cleaved upon secretion. However, some studies 
do hint that this may be true for certain PE/PPE proteins. For example, a 2-D gel analysis 
showed that a number of proteins dependent on ESX-5 for secretion into the culture were 
present at lower than expected molecular weights84. Several PE/PPE proteins were among 
this group. As the biological functions of additional PE/PPE proteins are uncovered, 
careful biochemical analysis will provide a better understanding of the full significance 
and functionality of PE/PPE domains. 
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CHAPTER 3: DISCUSSION 
Conclusions 
Until now, LipY has only been purified as a soluble aggregate, eluting only in the 
void volume from a gel filtration column86. Problems with the purification of LipY have 
mostly arisen as a result of the enzyme’s lipophylic properties. Denaturants such as urea, 
and detergents have been used to solubilize LipY when it has been expressed in E. coli. 
However, it has still proven difficult to purify LipY in a non-aggregate state. Here, I 
present a new a purification method for LipY that utilizes Tween 20 micelles to 
disaggregate aggregated LipY. Presumably, this method can be used to purify additional 
mycobacterial lipases and lipohilic proteins. Importantly, LipY variants (LipYΔPE and 
the PE domain) share similar properties as LipY when purified using this method. 
ABPP Method for Active Site Quantitation 
In addition to establishing a purification protocol for LipY, I also introduced a 
novel method for active site quantitation using activity-based protein profiling (ABPP). 
Generally, there are 2 methods used to quantify active enzyme molecules in vitro: 1) 
burst phase kinetics and 2) active site titration. With both approaches, either a well-
defined, active site-specific substrate or inhibitor is required. With regards to burst phase 
kinetics, usually either a chromogenic or fluorophore-containing substrate must be used 
in order to monitor enzyme activity. In addition, the rate of the reaction must also be 
considered in order to obtain data that reflects the rate of the enzymatic reaction as 
opposed to autohydrolysis (non-enzymatic activity). Active site titration methods also 
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require a tight-binding or covalent inhibitor specific to the enzyme’s active site. Residual 
enzyme activity can be measured and in some cases isothermal titration calorimetry (ITC) 
can be used to measure enzyme-inhibitor stoichiometry.  
Using ABPP, I have introduced a method of active site quantification that requires 
minimal reagents and is reliable. Generally, fluorescent ABPP is used to identify 
enzymes in a particular proteome by labeling cell lysates or subcellular fractions with a 
probe, separating the proteins using SDS-PAGE and performing an in-gel fluorescence 
analysis131. The cell fractions or lysates can also be manipulated by adding inhibitors or 
potential inhibitors to test their activities against enzymes within a particular proteome. In 
this work, I describe a method in which the commercially available serine hydrolase-
specific activity-based probe (ABP) is used to create a standard with as little as 2.5 pmols 
of the probe. Equal amounts of the serine hydrolase or serine hydrolases with an 
unknown active site concentration can then be labeled with a 1.5 fold molar excess of the 
ABP and reacted for 30 minutes. After labeling, the reaction is quenched with an excess 
of loading dye, boiled for 5-10 minutes, and separated using SDS-PAGE before 
performing in-gel fluorescence. Quantitation software is then used to quantify the ABP 
standard and the amount of labeled enzyme. This method produces a reliable value of the 
moles of active enzyme in a particular sample and, upon further testing, can be applied to 
quantifying lipases, serine proteases, esterases, cutinases and several other serine 
hydrolase family proteins.  
Testing Inhibitory Function of Candidate PE/PPE Domains 
It is still unclear whether or not the inhibitory role of the PE domain is a common 
function or is unique to LipY. In order to test the potentially ubiquitous inhibitory 
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property of PE and PPE domains, enzymatic assays similar to what have been described 
in this work could be carried out. There are 5 PE (Rv0151c, Rv0152c, Rv0159c, Rv0160c, 
Rv1430) and 3 PPE (Rv1800, Rv2608, Rv3539) proteins with predicted C-terminal α/β 
hydrolase folds based on in silico data36. It is therefore likely that these enzymes possess 
some sort of serine hydrolase activity (lipase, cutinase, esterase, protease, etc.).  For 
example, Rv1430 was subsequently discovered to possess esterase activity based on 
experimental data37. Therefore, it is plausible that, if PE/PPE domains act in a regulatory 
capacity in addition to their other functions such as targeting the protein to the cell wall, 
these 8 candidate PE/PPE domains may also possess that regulatory function. This 
hypothesis could be tested using chimeras with the candidate PE/PPE domains at the N-
terminus and the linker and lipase domains of LipY at the C-terminus.  
A similar enzymatic assay as described in the previous chapter can be used to test 
the putative inhibitor ability of candidate PE/PPE domains in the LipY-PE/PPE chimeras 
using the fluorogenic lipase substrate, DGGR. Based on the inhibitory function of LipY’s 
PE domain when attached to LipY, I anticipate that some, if not all, of the LipY-PE/PPE 
chimeras tested will possess some inhibitory function evidenced by a decreased 
maximum reaction velocity (Vmax). This result would suggest that a common inhibitory 
motif exists in some PE/PPE proteins. Another characteristic that would need to be 
considered when testing inhibition of LipY by candidate PE/PPE domains is whether or 
not those PE/PPE proteins are exported and whether or not the domains themselves are 
cleaved. This impacts how the inhibitory function of such domains can be exploited for 
therapeutic development. Only the LipY’s PE domain has been experimentally 
determined to be proteolytically cleaved after export to the cell wall although it has been 
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suggested that other PE/PPE domains may also be cleaved after export via the ESX-5 
secretion systems80,85. It is unclear whether or not the candidate PE/PPE proteins are 
exported and whether or not their respective PE or PPE domains are cleaved. 
Probing Enzymatic Functions of Candidate PE/PPE Proteins  
Only one of the 8 candidate PE/PPE proteins previously discussed has been 
successfully expressed, purified and had its enzymatic activity tested37. A likely reason 
for the lack of data concerning the 7 remaining PE/PPE proteins can likely be attributed 
to difficulties in purifying the proteins, as we know many PE/PPE proteins localize to the 
M. tuberculosis lipid-rich cell wall. The experiments described in the previous chapter 
provide a methodology for expressing, purifying and testing the activity of these putative 
enzymes. Here, I propose an approach that could provide at least two important pieces of 
information regarding PE/PPE proteins: 1) whether or not the 7 candidate PE/PPE 
proteins possess some hydrolase activity and 2) whether or not their PE/PPE domains 
possess some inhibitor function. We could clone, express and purify the previously 
mentioned PE/PPE candidates in the presence and absence of their PE or PPE domain 
using a similar approach used to purify LipY. Then, using p-Nitrophenly butyrate (pNPB), 
a general substrate with a short 4-carbon chain to test esterase activity, our lab could test 
the activities of the different variants. pNPB is a suitable substrate because it is unclear 
whether the candidates are lipase, cutinases, proteases, etc.  
The expected outcome from these experiments would be the discovery of 
additional PE/PPE proteins with C-terminal enzymatic domains. This would be a major 
discovery in defining the functions of PE/PPE proteins. The other potential outcome of 
these experiments would be the discovery of PE/PPE domains with inhibitory functions. 
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If we compared the activities of the full-length PPE candidate Rv1800 and its PPE 
domain mutant, for example, the mutant protein may have a higher Vmax, indicating it has 
an inhibitory role. The work presented here indicates that these possibilities are worth 
testing, are feasible and could be beneficial to researchers interested in PE/PPE proteins 
as therapeutic targets. 
Broader Implications  
The work presented in this body provides a template of sorts for recombinantly 
expressing, purifying, quantifying and measuring the enzymatic activity of potential PE 
and PPE proteins. This work also provides a framework for testing the inhibitory 
properties of PE and PPE domains against enzymatic activity. Future experiments, as 
proposed in this chapter, will likely result in a discovery of additional PE/PPE proteins 
with C-terminal hydrolase domains as well as the discovery of additional PE/PPE 
domains with regulatory properties. The discovery of previously unidentified PE/PPE 
enzymes could provide researchers with more information on how to best target these 
PE/PPE proteins with therapeutics.  
 It could also be the case that the outcomes of the proposed experiments are 
negative, indicating that LipY and Rv1430 are the only PE/PPE proteins with enzymatic 
functions. This outcome would also be beneficial to the scientific community as it would 
focus attention away from discovery of novel PE/PPE enzymes and towards better 
characterizing and targeting the current PE/PPE enzymes (LipY and Rv1430) for 
therapeutic discovery. In this scenario, which is the current state with respect to discovery 
of PE/PPE enzymes, researchers should consider the different catalytic properties of full 
length LipY (intracellular) and mature LipY (cell wall-associated) when assessing 
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accessibility of the target by inhibitors and screening inhibitors as this could affect the 
efficacy of the prospective therapeutic. Inhibitors targeting mature LipY located on the 
cell wall of M. tuberculosis would likely have a greater affect on M. tuberculosis growth 
compared to full length LipY as they would not have to cross the cell wall. 
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APPENDIX: SUPPORTING INFORMATION 
 
 
S Figure 1. LipY and LipYΔPE after Purification. 
(A) 50 pmoles each of LipY and LipYΔPE were loaded on a 12% SDS-PAGE gel, which 
was stained with Sypro Orange and imaged using a BioRad ChemiDoc™ Imaging 
System. The purity of the protein is demonstrated in the lane profiles to the right, which 
were analyzed using Image Lab 4.1. 
  
 53 
 
 
S Figure 2. LipY and LipYΔPE are Active on a Natural Triglyceride Substrate. 
LipY and LipYΔPE from Peak 2 (50 nM active protein) were incubated with triglyceride-
rich lipoprotein particles. Free fatty acids were released upon substrate hydrolysis; these 
were measured using a colorimetric assay as described in the supplemental methods. 
Three independent measurements were taken and error bars represent the standard 
deviation.  
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S Figure 3. Comparison of Equal Amounts of Active LipY from Peak 1 and Peak 2. 
The Vmax values for Peak 1 and 2 were adjusted using the active site quantitation shown 
in figure 4A. Values represent the Vmax for LipY in Peaks 1 and 2 per amount of active 
enzyme molecule. Error bars represent the standard error of the mean of 6 independent 
measurements. 
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S Figure 4. Active Site Titration and Kinetics of Lipy in Peak 1 and Peak 2. 
(A) Titration curve of LipY Peak 1 and Peak 2 inhibited with THL. Residual enzyme 
activity was measured using p-Nitrophenyl butyrate and normalized to uninhibited LipY. 
Activity versus ratio of THL to enzyme was plotted and the linear portions of each set of 
data were fit linearly. (B) Michaelis-Menten curves comparing equal amounts of total 
LipY from Peak 1 and Peak 2 using the DGGR substrate.  
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Supplemental Methods  
Isolation of Plasma Derived Triglycerides 
 Plasma derived triglyceride rich lipoprotein (TRL) particles were isolated as 
previously described132. 
Quantification of Substrate Triglyceride Levels 
 The triglyceride content of the sample was quantified as previously described 
with some modifications133. Briefly, samples were diluted in PBS and incubated with 
7.25 μM Candida Rugosa Lipase (Sigma Aldrich) in hydrolysis buffer (133 mM KPO4 
and 0.25% FFA BSA) for 30 minutes at 37 °C. Next, quantification buffer (133 mM 
KPO4, 3.3 mM McCl2, 4.4mM ATP, 0.6 mM TOOS, 6 U/mL POD, 1.73 mM 
bromophenol, 1.73 mM aminoantopyrine, 0.1 mM FAD, 0.5% Triton X-100, 0.25 U/mL 
Glycerol Kinase (Fisher Scientific), 4 U/mL Glycerolphosphate oxidase (Fisher 
Scientific)) was added each sample and allowed to incubate for 15 minutes at 37 °C. A 
sample containing no lipase was used for background subtraction for the hydrolyzed 
sample. Samples were read on a Spectromax M5 plate reader at 555 nm. Samples were fit 
to the standard curve to give the final triglyceride concentration. 
Triglyceride Hydrolysis Assays 
 Reaction samples were loaded into wells of a clear 96-well plate (Greiner). 50 nM 
LipY was incubated with TRLs (at a concentration of approximately 2.6 mM 
triglycerides). Individual reactions were quenched by the addition of Orlistat (Cayman 
Chemical Company, Ann Arbor, Michigan, USA) to a final concentration of 80 μM. 
Released free fatty acids (FFA) were quantified using a slight adaptation of a previously 
reported assay134. Briefly, reagent A (final concentrations: 133 mM KPO4 pH 7.5, 3.3 
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mM MgCl2, 4.4 mM ATP, 1 mM CoA, 0.055 U/mL ACS, 0.5% Triton X-100) was added 
to each sample (including palmitate standards) and the mixtures were incubated for 15 
minutes at 37°C. Reagent B (final concentrations: 133 mM KPO4 pH 7.5, 0.6mM TOOS, 
6 U/mL Horse POD, 1.73 mM dibromophenol, 1.73 mM 4-aminoantipyrine, 0.1 mM 
FAD, 10 mM NEM, 5 U/mL ACO, 0.5% Triton X-100) was then added to each sample 
and further incubated at 37°C for 10 minutes. Samples were assayed in triplicate. 
Samples were read on a Spectromax M5 plate reader at 555 nm. FFA release for each 
sample was quantified using a standard curve of palmitate. 
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